Drug Trial Radar · NCT06782373
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
May 28, 2025
Primary completion
Oct 30, 2028
Study completion May 22, 2030
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- PSI CRO
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. In phase 2a, approximately 78 participants will be randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. In Phase 2b, approximately 78 participants will be randomized. Phase 2b participants will initially be randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. After dose selection, Phase 2b further participants will be randomized to either the selected pacritinib dose or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Conditions
- VEXAS
- VEXAS Syndrome
Interventions
PacritinibDrug
Supplied in hard capsules.
PlaceboDrug
Supplied in hard capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR), defined as achieving Partial Clinical Response or better at any time during the double-blind treatment period.Time frame: up to End of Week 24
Locations
39 sites in 8 countries. Site status is shown where the registry gives one.
Sobi Investigative Site
Scottsdale, Arizona · Active not recruiting
Sobi Investigative Site
Boston, Massachusetts · Active not recruiting
Sobi Investigative Site
Rochester, Minnesota · Recruiting
Sobi Investigative Site
New York, New York · Active not recruiting
Sobi Investigative Site
Cleveland, Ohio · Active not recruiting
Sobi Investigative Site
Columbus, Ohio · Active not recruiting
Sobi Investigative Site
Houston, Texas · Active not recruiting
Sobi Investigative Site
Salt Lake City, Utah · Active not recruiting
Sobi Investigative Site
Seattle, Washington · Active not recruiting
Sobi Investigative Site
Vancouver, British Columbia, Canada · Recruiting
Sobi Investigative Site
Halifax, Nova Scotia, Canada · Recruiting
Sobi Investigative Site
Toronto, Ontario, Canada · Recruiting
Sobi Investigative Site
Montreal, Quebec, Canada · Active not recruiting
Sobi Investigative Site
Lille, France · Active not recruiting
Sobi Investigative Site
Paris, France · Active not recruiting
Sobi Investigative Site
Paris, France · Active not recruiting
Sobi Investigative Site
Pierre-Bénite, France · Active not recruiting
Sobi Investigative Site
Poitiers, France · Active not recruiting
Sobi Investigative Site
Toulouse, France · Active not recruiting
Sobi Investigative Site
Tübingen, Baden-Wurttemberg, Germany · Active not recruiting
Sobi Investigative Site
Munich, Bavaria, Germany · Active not recruiting
Sobi Investigative Site
Hamburg, Free and Hanseatic City of Hamburg, Germany · Active not recruiting
Sobi Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany · Active not recruiting
Sobi Investigative Site
Dresden, Saxony, Germany · Active not recruiting
Sobi Investigative Site
Lübeck, Schleswig-Holstein, Germany · Active not recruiting
Sobi Investigative Site
Milan, Italy · Active not recruiting
Sobi Investigative Site
Padova, Italy · Active not recruiting
Sobi Investigative Site
Reggio Emilia, Italy · Active not recruiting
Sobi Investigative Site
Roma, Italy · Active not recruiting
Sobi Investigative Site
Fukushima, Japan · Active not recruiting
Sobi Investigative Site
Nagasaki, Japan · Active not recruiting
Sobi Investigative Site
Yokohama, Japan · Active not recruiting
Sobi Investigative Site
Barcelona, Spain · Active not recruiting
Sobi Investigative Site
L'Hospitalet de Llobregat, Spain · Active not recruiting
Sobi Investigative Site
Salamanca, Spain · Active not recruiting
Sobi Investigative Site
Leeds, United Kingdom · Active not recruiting
Sobi Investigative Site
London, United Kingdom · Active not recruiting
Sobi Investigative Site
London, United Kingdom · Recruiting
Sobi Investigative Site
Oxford, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.